Abraxis Cited Again for cGMP Violations At Illinois Facility
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm tells “The Pink Sheet” DAILY it has taken “aggressive actions” in response to issues mentioned in a late 2006 FDA warning letter.
You may also be interested in...
Roche, Affitech Ink Development Deal For Oncology-Targeted Monoclonal Antibodies
Roche intends to commercialize cancer antibodies developed using Affitech’s phagemid technology, firms say.
Roche, Affitech Ink Development Deal For Oncology-Targeted Monoclonal Antibodies
Roche intends to commercialize cancer antibodies developed using Affitech’s phagemid technology, firms say.
Abraxane Randomized Trial Needed For Adjuvant Breast Cancer, Panel Says
ODAC votes in favor of Abraxis conducting an additional clinical trial to extend Abraxane’s indication from metastatic breast cancer into the adjuvant setting during a Sept. 7 meeting.